专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明专利

HK1122291A1 ANTI-VIRAL COMPOUNDS 未知
公开(公告)号：HK1122291A1
公开(公告)日：2009-05-15
申请号：HK09101287
申请日：2009-02-11
申请人： ABBOTT LAB
发明人： BETEBENNER DAVID A , DEGOEY DAVID A , MARING CLARENCE J , KRUEGER ALLAN C , IWASAKI NOBUHIKO , ROCKWAY TODD W , COOPER CURT S , ANDERSON DAVID D , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , LIU DACHUN , MCDANIEL KEITH F , MADIGAN DAROLD L , MOTTER CHRISTOPER E , PRATT JOHN K , SHANLEY JASON P , TUFANO MICHAEL D , WAGNER ROLF , ZHANG RONG , MOLLA AKHTERUZZAMAN , MO HONGMEI , PILOT-MATIAS TAMI J , MASSE SHERIE VL , CARRICK ROBERT J , HE WEPING , LU LIANGJUN , GRAMPOVNIK DAVID J
IPC分类号： C07D20060101
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

82. 发明专利

AU2008302448A1 Uracil or thymine derivative for treating hepatitis C 未知
公开(公告)号：AU2008302448A1
公开(公告)日：2009-03-26
申请号：AU2008302448
申请日：2008-09-17
申请人： ABBOTT LAB
发明人： HAIGHT ANTHONY R , RANDOLPH JOHN T , LONGENECKER KENTON L , FRANCZYK THADDEUS S II , BETEBENNER DAVID A , DEGOEY DAVID A , STEWART KENT D , TUFANO MICHAEL D , LIU YAYA , WAGNER ROLF , SARRIS KATHY , LIU DACHUN , BARNES DAVID M , ROCKWAY TODD W , FLENTGE CHARLES A , KATI WARREN M , KOTECKI BRIAN J , ZHANG GEOFF G Z , CHEN SHUANG , GAO YI , HENRY RODGER F , HUANG PEGGY P , PRATT JOHN K , DONNER PAMELA L , MARING CLARENCE J , HUTCHINSON DOUGLAS K , KRUEGER ALLAN C , LOU XIAOCHUN , MOTTER CHRISTOPHER E , HENGEVELD JOHN E
IPC分类号： C07D239/22 , A61K31/513 , A61P31/12 , C07D239/54 , C07D401/10 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia , inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; and (e) use of such compounds, salts, and compositions.

83. 发明专利

BR0315897A 未知
公开(公告)号：BR0315897A
公开(公告)日：2008-05-13
申请号：BR0315897
申请日：2003-10-31
申请人： ABBOTT LAB
发明人： PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC分类号： C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D513/14 , C07D519/00
摘要： The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided. formula (I)

84. 发明专利

PL376823A1 Środki przeciwzakaźne 未知
公开(公告)号：PL376823A1
公开(公告)日：2006-01-09
申请号：PL37682303
申请日：2003-10-31
申请人： ABBOTT LAB
发明人： PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC分类号： C07D471/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D495/04 , C07D513/04 , C07D519/00

85. 发明专利

AU2003291670A1 ANTI-INFECTIVE AGENTS 未知
公开(公告)号：AU2003291670A1
公开(公告)日：2004-06-07
申请号：AU2003291670
申请日：2003-10-31
申请人： ABBOTT LAB
发明人： PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC分类号： A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04 , C07D519/00 , C07D513/14 , A61K31/554
摘要： The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided. formula (I)

86. 发明专利

CO5261499A1 INHIBIDORES DE NEURAMINIDASAS 未知
公开(公告)号：CO5261499A1
公开(公告)日：2003-03-31
申请号：CO00079306
申请日：2000-10-18
申请人： ABBOTT LAB
发明人： MARING CLARENCE J , YU-GUI GU , HUI-JU CHEN , YUANWEI CHEN , DEGOEY DAVID A , FIOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , WARREN M KATI , KEMPF DALE J , APRIL L KENNEDY , KLEIN LARRY L , KRUEGER ALLAN C , ZHEN LIN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , KENT D STEWART , STOLL VINCENT S , MINGHUA SUN , NOAH P TU , WAGENAAR FRANK L , WANG GARY T , SHELDON WANG , WIEDEMAN PAUL E , YIBO XU , MING C YEUNG , CHEN ZHAO , STEOHEN HANESSIAN , MALKEN BAYRAKDARIAN , XUEHONG LUO
IPC分类号： C07D401/12 , A61K31/16 , A61K31/341 , A61K31/357 , A61K31/381 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/405 , A61K31/415 , A61K31/4155 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/427 , A61K31/4439 , A61K31/5377 , A61K31/66 , A61K31/662 , A61P31/00 , A61P31/12 , A61P31/16 , A61P43/00 , C07D20060101 , C07D207/00 , C07D207/12 , C07D207/16 , C07D207/26 , C07D207/32 , C07D207/327 , C07D207/38 , C07D207/46 , C07D303/16 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D407/06 , C07D407/12 , C07D409/06 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/40 , C07F9/572
摘要： Un compuesto enriquecido enantioméricamente CARACTERIZADO PORQUE tiene la estereoquímica absoluta de la fórmula: o una sal, un éster o una prodroga aceptable para uso farmacéutico de los mismosdonde R1 se selecciona del grupo formado por (a) -CO2H, (b) -CH2CO2H, (c) -SO3H, (d) -CH2SO3H, (e) -SO2H, (f) -CH2SO2H, (g) -PO3H2, (h) -CH2PO3H2, (i) -PO2H, o) -CH2PO2H, (k) tetrazolilo, (l) -CH2-tetrazolilo, (m) -C(=O)-NH-S(O)2-R11, (n) -CH2C(=O)-NH-S(O)2-R11, (o) -SO2N(T-R11)R12 y (p) -CH2SO2N(T-R11)R12donde T se selecciona del grupo formado por (i) un enlace, (ii) -C(=O)-, (iii) -C(=O)O-, (iv) -C(=O)S-, (v) -C(O)NR36, (vi) -C(=S)O-, (vii) -C(=S)S- y (viii) -C(=S)NR36-,R11 se selecciona del grupo formado por(i) C1-C12-alquilo, (ii) C2-C12 -alquenilo, (iii) cicloalquilo, (iv) (cicloalquil)alquilo, (v) (cicloalquil)alquenilo, (vi) cicloalquenilo, (vii) (cicloalquenil)alquilo, (viii) (cicloalquenil)alquenilo, (ix) arilo, (x) (aril)alquilo, (xi) (aril)alquenilo, (xii) heterocíclico, (xiii) alquilo(heterocíclico) y (xiv) alquenilo(heterocíclico); y R12 y R36 se selecionan independiente entre sí, del grupo formado - 2 -(i) hidrógeno, (ii) C1-C12-alquilo, (iii) C1-C12-alquenilo, (iv) cicloalquilo (v) (cicloalquil)alquilo, (vi) (cicloalquil)alquenilo, (vii) cicloalquenilo, (viii) (cicloalquenil)alquilo, (ix) (cicloalquenil)alquenilo, (x) arilo, (xi) (aril)alquilo, (xii) (aril)alquenilo, (xiii) heterocíclico, (xiv) alquilo (heterocíclico) y (xv) alquenilo(heterocíclico)X se selecciona del grupo formado por (a -C(=O)-N(R*)-, (b)-N(R*)-C(=O)-, (c)-C(=S)-N(R*)-, (d) -N(R*)-C(=S)-, (e)-N(R*)-SO2-, y M -SO2-N(R*)-, donde R* es hidrógeno, C1-C3-alquilo inferior o ciclopropilo, R2 se selecciona del grupo formado por (a) hidrógeno, (b) C1-C6-alquilo, (C) C2-C6-alquenilo, (d) C3C6 cicloalquilo, (e) C5-C6-cicloalquenilo, (f) halo-C1-C6-alquilo y (g) halo-C2-C6-alquenilo; o R2-X es donde Y1 es -CH2-, -O-, -S- o -NH- e Y2 es -C(=O)- o -C(Raa)(Rbb), donde Raa y Rbb se seleccionan, independientemente entre sí, del grupo formado por hidrógeno, C1-C3-alquilo inferior, hidroximetilo, 1 -hidroxietilo, 2-hidroxietilo, aminometilo, 1-aminoetilo, 2-aminoetilo, tiolmetilo, 1-tioletilo, 2-tioletilo, metoximetilo, N-metilaminometilo y metiltiometilo; R3 y R4 se seleccionan, independientemente entre sí, del grupo formado por (a) hidrógeno, (b) cicloalquilo, (c) cicloalquenilo, (d) heterocíclico, (e) arilo y (f) -Z-R14 donde Z es (i) -C(R37a)(R37b)-, (ii)-C(R47)=C(R48)-, (iii)-C=C-, (iv) -C(=O)-(v) -C(=S)-, (vi) -C(=NR15)-, (vii) -C(R37a)(OR37c)-, (viii) -C(R37a)(SR37c)-, (ix) -C(R37a)(N(R37b)(R37c))-, (x) -C(R37a)(R37b)-O-, (xi) -C(R37a)(R37b)-N(R37c)-, (xii) -C(R37a)(R37b)-N(O)(R37c), (xiii) -C(R37a)(R37b)-N(OH)-, (xiv) -C(R37a)(R37b)-S-, (xv) -C(R37a)(R37b)-S(O), (xvi) -C(R37a)(R37b)-S(O)2-, (xvii) -C(R37a)(R37b)-C(=O)-, (xviii) -C(R37a)(R37b)-C(=S)-, (xix) -C(R37a)(R37b)-C(=NR15)-, (xx) -C(R37a)(OR37c)-C(=O)-, (xxi) -C(R37a)(SR37b)-C(=O)-, (xxii) -C(R37a)(R37c)-C(=S)-, (xxiii) -C(R37a)(SR37c)-C(=S)-, (xxiv) -C(=O)-C(R37a)(OR37c)-, (xxv) -C(=O)-C(R37a)(SR37c)-, (xxvi) -C(=S)-C(R37a)(OR37c)-, (xxvii) -C(=S)-C(R37a)(SR37c)-, (xxviii) -C(R37a)(OR37c)-C(R37a)(OR37c)-, (xxix)-C(R37a)(SR37c)-C(R37a)(OR37c)-, (xxx) -C(R37a)(OR37c)-C(R37a)(SR37c)-, (xxxi) -C(R37a)(SR37c)-C(R37a)(SR37c)-, (xxxii) -C(=O)-C(=O)-, (xxxiii) -C(=S)-C(=S)-, (xxxiv) -C(=O)-O-, (xxxv) -C(=O)-S-, (xxxvi) -C(=S)-O-, (xxxvii) -C(=S)-S-, (xxxviii) -C(=O)-N(R37a)- (xxxix) -C(=S)-N(R37a)-, (xI) -C(R37a)(R37b)-C(=O)-N(R37a)-, (xli) -C(R37a)(R37b)-C(=S)-N(R37a)-, (xlii) -C(R37a (R37b)-C(=O)-O-, (xliii) -C(R37a)(R37b)-C(=O)-S-, (xliv) -C(R37a)(R37b)-C(=S)-O, (xlv) -C(R37a)(R37b)-C(=S)-S-, (xlvi) -C(37a)(R37b)N(R37b)-C(=O)-, (xlvii) -C(R37a)(R37b)-N(R37b)-C(=S)-, (xlviii) -C(R37a)(R37b)-O-C(=O)- (xlix) -C(R37a)(R37b)-S-C(=O)-, (l) -C(R37a)(R37b)-O-C(=S)-, (li) -C(R37a)(R37b)-S-C(=S)-, (Iii) -C(R37a)(R37b)-N(R37b)-C(=O)-N(R37a)-, (Iiii) -C(R37a)(R37b)-N(R37b)-C(=S)-N(R37a)-, (liv) -C(R37a)(R37b)-N(R37b)-C(=O)-O-, (Iv) -C(R37a) (R37b)-N(R37b)-C(=O)-S-, (Ivi) -C(R37a)(R37b)-N(R37b)-C(=S)-O-, (lvii) -C(R37a)(R37b)-N(R37b)-C(=S)-S-, (lviii) -C(R37a)(R37b)-O-C(=O)-N(R37a)-, (lix) -C(R37a)(R37b)-S-C(=O)-N(R37a)-, (Ix) -C(R37a)(R37b)-O-C(=S)-N(R37a)-, (Ixi) -C(R37a)(R37b)-S-C(=S)-N(R37a)-, (Ixii) -C(R37a)(R37b)-O-C(=O)-O-, (Ixiii) -C(R37a)(R37b)-S-C(=O)-O-, (Ixiv) -C(R37a)(R37b)-O-C(=O)-S-, (Ixv) -C(R37a)(R37b)-S-C(=O)-S-, (Ixvi) -C(R37a)(R37b)-O-C(=S)-O-, (Ixvii) -C(R37a)(R37b)-S-C(=S)-O-, (lxviii) -C(R37a)(R37b)-O-C(=S)-S-, (Ixix) -C(R37a)(R37b)-S-C(=S)-S- o (Ixx) -C(R37a)(R37b)-C(R37a)(OR37c); R14 es (i) hidrógeno, (ii) C1-CI2-alquilo, (iii) haloalquilo, (iv) hidroxialquilo, (v) alquilo tiol-sustituido, (vi) alquilo R37c-O-sustituido, (vii) alquilo R37c-S-sustituido, (viii) aminoalquilo, (ix) alquilo (R37C)NH-sustituido, (x) alquilo (R37a)(R37c)N- sustituido, (xi) alquilo R37aO-(O=)C-sustituido, (xii) alquilo R37a-S-(O=)C sustituido, (xiii) alquilo R37aO-(S=)C-sustituido, (xiv)alquilo R37a-S-(S=)C sustituido, (xv) alquilo (R37aO)2-P(=O)-sustituido, (xvi) cianoalquilo, (xvi)C1-C12- alquenilo, (xviii) haloalquenilo, (xix) C2-C12-alquinilo, (xx) cicloalquilo, (xxi) (cicloalquil)alquilo, (xxii) (cicloalquil)alquenilo, (xxiii) (cicloalquil)alquinilo, (xxiv) cicloalquenilo (xxv) (cicloalquenil) alquilo, (xxvi) - 3 -(cicloalquenil)alquenilo, (xxvii) (cicloalquenil)alquinilo, (xxviii) arilo, (xxix) (aril) alquilo, (xxx) (aril)alquenilo, (xxxi) (aril)alquinilo, (xxxii) heterocíclico, (xxxiii) alquilo (heterocíclico), (xxxiv) alquenilo(heterocíclico) o (xxxv) (heterocíclico)alquinilo, con la condición que R14 es distinto de hidrógeno cuando Z es -C(R37a)(R37b)-N(R37b)-C(=O)-(O)-, -C(R37a)(R37b)-N(R37b)-C(=S)-O-, -C(R37a)(R37b)-N(R37b)-C(=O)-O-, -C(R37a)(R37b)-N(R37b)-C(=S)-S-, -C(R37a)(R37b)-O-C(=O)-O-, -C(R37a)(R37b)-O-C(=S)-O-, -C(R37a)(R37b)-S-C(=O)-O-, -C(R37a)(R37b)-S-C(=S)-O-, -C(R37a)(R37b)-O-C(=O)-S-, -C(R37a)(R37b)-O-C(=S)-S-, C(R37a)(R37b)-S-C(=O)S o -C(R37a)R37b)-S-C(=S)-S-; R37a, R37b y R47 y R48 se seleccionan en cada aparición, independientemente entre sí, del grupo formado por (i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) hidroxialquilo, (v) alcoxialquilo, (vi) C2-C12-alquenilo, (vii) haloalquenilo, (viii) C2-C12-alquinilo, (ix) cicloalquilo, (x) (cicloalquil)alquilo, (xi) (cicloalquil)alquenilo, (xii) (cicloalquil)alquinilo, (xiii) cicloalquenilo, (xiv) (cicloalquenil) alquilo, (xv) (cicloalquenil)alquenilo, (xvi) (cicloalquenil)alquinilo, (xvii) arilo, (xviii) (aril)alquilo, (xix) (aril)alquenilo, (xx)(aril)alquinilo, (xxi)heterocíclico, (xxii) alquilo(heterocíclico), (xxiii) alquenilo(heterocíclico) y (xxiv) alquinilo(heterocíclico), R37c se selecciona en cada aparición, independientemente, del grupo formado por (i) hidrógeno, (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) C2-C12-alquenilo, (v) haloalquenilo, (vi) C2-C12-alquinilo, (vii) cicloalquilo, (viii) (cicloalquil)alquilo, (ix) (cicloalquil)alquenilo, (x) (cicloalquil) alquinilo, (xi) cicloalquenilo, (xii) (cicloalquenil)alquilo, (xiii) (cicloalquenil)alquenilo, (xiv) (cicloalquenil)alquinilo, (xv) arilo, (xvi) (aril)alquilo, (xvii) (aril)alquenilo, (xviii) (aril)alquinilo, (xix) heterocíclico, (xx) alquilo(heterocíclico), (xxi) alquenilo(heterocíclico), (xxii) alquinilo (heterocíclico), (xxiii)-O(=O)-R14, (xxiv)-C(=S)-R, (xxv)-S(O)2-R14 y (xxvi) hidroxialquilo; o cuando Z es -C(R37a)(R37b)-N(R37c)-, entonces cuando N(R37c) y R14 se toman juntos constituyen un grupo azido; o cuando Z es -C(R37a)(R37b)-N(O)(R37c)-, entonces cuando N(O)(R37c) y R14 se toman juntos constituyen un anillo heterocíclico de 3-7 miembros N-oxidado que posee por lo menos un átomo de nitrógeno en el anillo N-oxidado, o cuando Z es -C(R37a)(OR37b)-, -C(R37a)(SR37c)-o- -C(R37a)(N(R37b)(R37c))-, entonces R37a, R14 y el átomo de carbono al que están unidos cuando se toman juntos forman un anillo ciclopentilo, ciclopentenilo, ciclohexilo o ciclohexenilo o entonces OR37c o SR37c o N(R37c) y R14 y el átomo de carbono al que están unidos cuando se toman juntos forman un anillo heterocíclico que contiene un átomo de O, S o N, respectivamente, y contiene entre 4 y 8 átomos del anillo; R15 se selecciona del grupo formado por (i) hidrógeno, (ii) hidroxi, (iii) amino, (iv) C1-C12-alquilo, (v) haloalquilo, (vi) C2-C12-alquenilo (vii) haloalquenilo, (viii) cicloalquilo (ix) (cicloalquil)alquilo, (x) (cicloalquil)alquenilo, (xi) cicloalquenilo, (xii) (cicloalquenil)alquilo, (xiii) (cicloalquenil)aIquenilo, (xiv) arilo, (xv) (aril)alquilo, (xvi)(aril)alquenilo, (xvii) heterocíclico, (xviii) alquilo(heterocíclico) y (xix) alquenilo(heterocíclico), o R3 y R4 tomados juntos, con el átomo al cual están unidos, forman un anillo carbocíclico o heterocíclico que posee de 3 a 8 átomos en el anillo, R5 se selecciona del grupo formado por (a) hidrógeno, (b) -CH(R38)2, (c) -O-R40, (d) C2-C4-alquinilo, (e) ciclopropilo, (f) ciclobutilo, (g) -C(=Q1)-R17 y (h) -N(R19)2 donde Q1 es O, S o N(R18); R17 y R18 se seleccionan Independientemente, en cada aparición, del grupo formado por hidrógeno, metilo y etilo; R19, R38 y R40 se seleccionan independientemente, en cada aparición, del grupo formado por (i) hidrógeno (ii) C1-C12-alquilo, (iii) haloalquilo, (iv) C2-C12-alquenilo, (v) haloalquenilo, (vi) cicloalquilo, (vii) (cicloalquil)alquilo, (viii) (cicloalquil)alquenilo, (ix) cicloalquenilo, (x) (cicloalquenil)alquilo, (xi) (cicloalquenil)alquenilo, (xii) arilo, (xiii) (aril)alquilo (xiv) (aril)alquenilo, (xv) heterocíclico, (xvi) alquilo(heterocíclico) y (xvii) alquenilo(heterocíclico);Y se selecciona del grupo formado por - 4 -(a) hidrógeno, (b) C1-C5-alquilo, (c) C1-C5-haloalquilo, (d) C2-C5-alquenilo, (e) C2-C5-haloalquenilo, (f) C2-C5-alquinilo, (g) C3-C5-cicloalquilo, (h C3-C5-cicloalquil-C1-a-C3-alquilo, (i) C5-cicloalquenilo, (j) C5-cicloalquenil-C1-a-C3-alquilo, (k) C5-cicloa

88. 发明专利

AU8005100A Inhibitors of neuraminidases 未知
公开(公告)号：AU8005100A
公开(公告)日：2001-04-30
申请号：AU8005100
申请日：2000-10-10
申请人： ABBOTT LAB
发明人： MARING CLARENCE J , GIRANDA VINCENT L , KEMPF DALE J , STOLL VINCENT S , SUN MINGHUA , ZHAO CHEN , GU YU GUI , WANG GARY T , KRUEGER ALLAN C , CHEN YUANWEI , DEGOEY DAVID A , GRAMPOVNIK DAVID J , KATI WARREN M , KENNEDY APRIL L , LIN ZHEN , MADIGAN DONALD L , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , WANG SHELDON , YEUNG MING C
IPC分类号： A61K31/195 , C07C233/48 , C07C237/24 , C07C271/22 , C07C271/24 , C07C279/16 , C07D233/54 , C07D263/32 , C07D307/24 , C07D317/30 , C07D405/04 , C07C233/00
摘要： Disclosed are compounds of the formula:which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

89. 发明专利

CA2388859A1 INHIBITORS OF NEURAMINIDASES 未知
公开(公告)号：CA2388859A1
公开(公告)日：2001-04-26
申请号：CA2388859
申请日：2000-10-10
申请人： ABBOTT LAB
发明人： MARING CLARENCE J , WAGENAAR FRANK L , WANG SHELDON , GIRANDA VINCENT L , LIN ZHEN , FLOSI WILLIAM J , DEGOEY DAVID A , KLEIN LARRY L , KEMPF DALE J , STOLL VINCENT S , KATI WARREN M , GRAMPOVNIK DAVID J , KENNEDY APRIL L , WIEDEMAN PAUL E , MCDANIEL KEITH F , TU NOAH P , XU YIBO , HANESSIAN STEPHEN , STEWART KENT D , SHAM HING L , MUCHMORE STEVEN W , WANG GARY T , BAYRAKDARIAN MALKEN , LUO XUEHONG , CHEN YUANWEI , MADIGAN DAROLD L , YEUNG MING C , ZHAO CHEN , KRUEGER ALLAN C , GU YU GUI , CHEN HUI-JU , SUN MINGHUA
IPC分类号： C07D401/12 , A61K31/357 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/405 , A61K31/415 , A61K31/4155 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/427 , A61K31/4439 , A61K31/5377 , A61K31/66 , A61K31/662 , A61P31/00 , A61P31/12 , A61P31/16 , A61P43/00 , C07D20060101 , C07D207/00 , C07D207/12 , C07D207/16 , C07D207/26 , C07D207/32 , C07D207/327 , C07D207/38 , C07D207/46 , C07D303/16 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D407/06 , C07D407/12 , C07D409/06 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/40 , C07F9/572
摘要： Enantiomerically enriched compounds having the absolute stereochemistry of t he formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式